The New York Times, June 27, 2013
Bert Vogelstein, a cancer geneticist at Johns Hopkins University, says he is haunted by three pictures.
The first shows a man’s upper body studded with large melanomas. The second shows what happened when the man took a drug called vemurafenib. Vemurafenib belongs to a relatively new class of drugs, called targeted cancer therapy. Unlike earlier chemotherapy drugs, they attack specific molecules found only in cancer cells. In response to the vemurafenib, the tumors shrank in a matter of weeks, to the point that the man’s skin looked smooth and healthy.
Continue reading “Studying Tumors Differently, in Hopes of Outsmarting Them”